Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma - Trial NCT05993299
Access comprehensive clinical trial information for NCT05993299 through Pure Global AI's free database. This Phase 2 trial is sponsored by GlaxoSmithKline and is currently Recruitment Completed. The study focuses on Neoplasms. Target enrollment is 7 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GlaxoSmithKline
Timeline & Enrollment
Phase 2
Dec 31, 2019
Jul 01, 2024
Primary Outcome
Overall Response Rate (ORR)
Summary
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in
 participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05993299
Non-Device Trial